Immune Archetecture of Stage 4 Triple-Negative Breast Cancer
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Jacksonville, Florida: 22-001887
Sponsor Protocol Number: 22-001887
About this study
The purpose of this study is to identify who may or may not be a good fit for specific cancer treatments. Investigators will be attempting to identify markers that may make someone resistant to specific therapies in order to avoid harsh treatments that would not be effective or target more effective treatments at the offset.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- Patients must be 18 and older.
- Patients with stage I-III or unresectable locally advanced or metastatic stage IV triple-negative breast cancer:
- Estrogen and progesterone receptors negative per ASCO/CAP guideline; AND
- HER2 negative per ASCO/CAP guideline.
- Treated with pembrolizumab or atezolizumab in combination with chemotherapy in the metastatic setting.
- Adequate available archived breast tumor, normal, and lymph node tissue from either biopsies or surgery from which slides can be prepared.
Exclusion Criteria:
- Patients with insufficient archived tumor or lymph node material to provide at least 3 unstained slides at 5-micron sections.
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 6/8/23. Questions regarding updates should be directed to the study team contact.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Jacksonville, Fla.
Mayo Clinic principal investigator Saranya Chumsri, M.D. |
Open for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available